Advanced in Pseudomyxoma Peritonei

Dr. Bernice L. Robinson-Bennett

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Reading Hospital
206 S 6th Ave, 
West Reading, PA 
Advanced in Pseudomyxoma Peritonei
Reading Hospital
206 S 6th Ave, 
West Reading, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bernice Robinson-Bennett is a Gynecologic Oncologist and an Oncologist in West Reading, Pennsylvania. Dr. Robinson-Bennett is rated as an Advanced provider by MediFind in the treatment of Pseudomyxoma Peritonei. Her top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Cervical Cancer, and Bladder Reconstruction.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in TX
Hospital Affiliations
Pottstown Hospital
Reading Hospital
Phoenixville Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Capital Blue Cross
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
PA Health and Wellness
  • HMO
  • MANAGED MEDICAID PLAN
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

READING HOSPITAL
206 S 6th Ave, West Reading, PA 19611
Other Locations
READING HOSPITAL
420 S 5th Ave, West Reading, PA 19611

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Completed
Publish Date: May 23, 2025
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination With Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)
Enrollment Status: Active_not_recruiting
Publish Date: December 10, 2024
Intervention Type: Other, Drug, Biological
Study Drugs: Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 13, 2023
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
A Randomized Trial of Pelvic Irradiation With or Without Concurrent Weekly Cisplatin in Patients With Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
Enrollment Status: Unknown
Publish Date: March 29, 2023
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
A Phase III Randomized Trial of Pulse Actinomycin-D Versus Multi-day Methotrexate for the Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Enrollment Status: Completed
Publish Date: August 12, 2022
Intervention Type: Other, Drug, Biological
Study Drugs: Dactinomycin, Leucovorin Calcium, Methotrexate
Study Phase: Phase 3
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 6 Less Clinical Trials

3 Total Publications

Surgically Enucleated Gastrointestinal Tumor of the Rectovaginal Septum.
Surgically Enucleated Gastrointestinal Tumor of the Rectovaginal Septum.
Journal: Cureus
Published: September 10, 2019
Similar Doctors
Distinguished in Pseudomyxoma Peritonei
Dr. Nawar Latif
Oncology
Distinguished in Pseudomyxoma Peritonei
Dr. Nawar Latif
Oncology

Penn Gynecologic Oncology Washington Square

800 Walnut Street, 10th Floor, 
Philadelphia, PA 
 (49.7 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Nawar Latif is an Oncologist in Philadelphia, Pennsylvania. Dr. Latif is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Pseudomyxoma Peritonei, Testicular Yolk Sac Tumor, Virilizing Ovarian Tumor, Splenectomy, and Bladder Reconstruction. Dr. Latif is currently accepting new patients.

Distinguished in Pseudomyxoma Peritonei
Dr. Janos L. Tanyi
Oncology
Distinguished in Pseudomyxoma Peritonei
Dr. Janos L. Tanyi
Oncology

Jordan Center For Gynecologic Cancers

3400 Civic Center Boulevard, West Pavilion, 3rd Floor, 
Philadelphia, PA 
 (48.1 miles away)
800-789-7366
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Janos Tanyi is an Oncologist in Philadelphia, Pennsylvania. Dr. Tanyi is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, Ureteroscopy, and Bladder Reconstruction. Dr. Tanyi is currently accepting new patients.

Advanced in Pseudomyxoma Peritonei
Dr. Stephen C. Rubin
Gynecologic Oncology | Oncology
Advanced in Pseudomyxoma Peritonei
Dr. Stephen C. Rubin
Gynecologic Oncology | Oncology

Temple Faculty Practice Plan Inc

3401 N Broad St, 
Philadelphia, PA 
 (47.9 miles away)
215-707-3326
Languages Spoken:
English
See accepted insurances

Stephen Rubin is a Gynecologic Oncologist and an Oncologist in Philadelphia, Pennsylvania. Dr. Rubin is rated as a Distinguished provider by MediFind in the treatment of Pseudomyxoma Peritonei. His top areas of expertise are Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Robinson-Bennett's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 32 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile